‘Difficult-to-treat’ immune-mediated inflammatory diseases call for holistic strategy

The emergence of biologic therapies ushered in an era of unprecedented positive outcomes for patients with rheumatic and autoimmune diseases. However, 30 years after the start of rheumatology’s “biologic era,” many patients still fail to respond to those medications, giving rise to a group of patients often described as “difficult to treat.”